References
Association of British Pharmaceutical Industry and the Department of Health. The Pharmaceutical Price Regulation Scheme 2009 [online]. Available from URL: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_098498.pdf [Accessed 2011 May 19]
Office of Fair Trading. The Pharmaceutical Price Regulation Scheme: anOFT market study. London: OFT, 2007 [online]. Available from URL: http://www.oft.gov.uk/shared_oft/reports/comp_policy/oft885.pdf [Accessed 2011May 19]
Department of Health. A new value-based approach to the pricing of branded medicines: a consultation, 2010 [online]. Available from URL: http://www.dh.gov.uk/en/Consultations/Closedconsultations/DH_122760 [Accessed 2011 May 19]
Towse A. Value based pricing, research and development, and patient access schemes: will the United Kingdom get it right or wrong? Br J Clin Pharmacol 2010; 70 (3): 360–6
Office for National Statistics. Statistical bulletin: UK business enterprise research and development 2009 [online]. Available from URL: http://www.statistics.gov.uk/pdfdir/berd1210.pdf [Accessed 2011 May 19]
Joint Formulary Committee. British national formulary. London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society, 2011: 61
Kaplan W, Laing R. Priority medicines for Europe and the world. WHO, Department of Essential Drugs and Medicines [policy document WHO/EDM/PAR/2004.7]. Geneva: WHO, 2004 [online]. Available from URL: http://whqlibdoc.who.int/hq/2004/WHO_EDM_PAR_2004.7.pdf [Accessed 2011 May 19]
Webb DJ, Walker A. Value-based pricing of drugs in the UK. Lancet 2007; 369 (9571): 1415–6
Claxton K. OFT, VBP: QED? Health Econ 2007 Jun; 16 (6): 545–58
McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008; 26 (9): 733–44
Sculpher S, Claxton K, Martin S, et al. Methods for estimation of the NICE cost-effectiveness threshold. Medical Research Council Methodology Research Programme [online]. Available from URL: http://www.york.ac.uk/che/research/teams/teehta/projects/methodological-research/workshop-held-at-imperial-college-london/ [Accessed 2011May 19]
Martin S, Rice N, Smith PC. Does health care spending improve health outcomes? Evidence from English programme budgeting data. J Health Econ 2008; 27: 826–42
Martin S, Rice N, Smith PC. The link between health spending and health outcomes for the new English primary care trusts. London: The Health Foundation, 2009
HM Treasury. Public expenditure by country, region and function [online]. Available from URL: http://www.hm-treasury.gov.uk/d/pesa_2010_chapter9.pdf [Accessed 2011 May 19]
National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008 [online]. Available from URL: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed 2011 May 19]
Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur J Health Econ 2010; 11: 195–203
Williamson S. Patient access schemes for high-cost cancer medicines. Lancet Oncol 2010; 11: 111–2
Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ 2010; 340: c1672
Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008; 336 (7638): 251–4
Claxton K, Sculpher M, Carroll S. Value-based pricing for pharmaceuticals: its role, specification and prospects in a newly devolved NHS [Centre for Health Economics Research Paper 60]. York: University of York, 2011 [online]. Available from URL: http://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP60.pdf [Accessed 2011 May 19]
Hawkins N, Scott DA. Reimbursement and value-based pricing: stratified cost-effectiveness analysis may not be the last word. Health Econ 2011; 20: 688–98
National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments. London: NICE, 2009 [online]. Available from URL: http://www.nice.org.uk/media/E4A/79/SupplementaryAdviceTACEoL.pdf [Accessed 2011 May 19]
NHS Health and Social Care Information Centre. Use of NICE appraised medicines in the NHS in England: 2009, experimental statistics. London: Prescribing Support Unit, 2009 [online]. Available from URL: http://www.ic.nhs.uk/webfiles/publications/007_Primary_Care/niceappmed0910/NICE_bulletin_2009.pdf [Accessed 2011 May 19]
Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol 2010; 70 (3): 335–41
Rawlins M, Barnett D, Stevens A. Pharmacoeconomics: NICE’s approach to decision-making. Br J Clin Pharmacol 2010; 70 (3): 346–9
All Wales Medicines Strategy Group. Guidelines for appraising medicines. 2011 [online]. Available from URL: http://www.wales.nhs.uk/sites3/Documents/371/Guidelines%20for%20appraising%20medicines.pdf [Accessed 2011 May 19]
Hughes DA, Ferner RE. New drugs for old: disinvestment and NICE. BMJ 2010; 340: c572
Ferner RE, Hughes DA, Aronson JK. NICE and new: appraising innovation. BMJ 2010; 340: b5493
Walker A, Booth C, Brown A, et al. How much good do new medicines do? [abstract]. Basic Clin Pharmacol 2009; 105 Suppl. 1: O23
HM Treasury. Part IIB: the taxation of innovation and intellectual property. Corporate tax reform: delivering a more competitive system, 2010 [online]. Available from URL: http://www.hm-treasury.gov.uk/d/corporate_tax_reform_part2b_innovation_and_intellectual_property.pdf [Accessed 2011 May 19]
GlaxoSmithKline. Government patent box proposals ‘transform’ UK attractiveness for investment [media release]. London: GlaxoSmithKline, 2010 Nov 29 [online]. Available from URL: http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10124.htm [Accessed 2011 May 19]
Kesselheim AS. Using market-exclusivity incentives to promote pharmaceutical innovation. N Engl J Med 2010; 363 (19): 1855–62
Acknowledgements
No sources of funding were used to prepare this manuscript. The author has no conflicts of interest that are directly relevant to the content of this editorial. The author is grateful to Professor Mark Sculpher for his helpful comments.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hughes, D.A. Value-Based Pricing. Pharmacoeconomics 29, 731–735 (2011). https://doi.org/10.2165/11592570-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11592570-000000000-00000